Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday reported promising results from its Phase 2/3 COVA study of oral BIO101 (20-hydroxyecdysone) in the treatment of severe COVID-19 in hospitalised adults.
The findings were presented at the World Congress on Infectious Diseases in Paris, France.
Biophytis reported a statistically significant 43.8% reduction in the risk of early respiratory failure or death, along with a 44.6% reduction in the 90-day death rate. These positive findings come amid rising COVID-19 cases.
Epigenic Therapeutics receives New Zealand approval for EPI-003 clinical trial
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Seegene finalises Werfen partnership agreement
hVIVO reports positive results from RSV antiviral human challenge trial
Gilead expands global access to lenacapavir for HIV prevention